Saultz and Lochner’s research have long highlighted how relational continuity enhances trust, communication, and shared ...

The FDA has a new director for the Center for Drug Evaluation and Research (CDER), with biopharma industry executive George ...

On day three of BIO 2025, editor-in-chief Jonah Comstock caught up with OS Therapeutics CEO Paul Romness and EVERSANA VP of ...

A once-daily tablet that can help people suffering from hay fever caused by birch tree pollen, Alk-Abelló's Itulazax, has ...

AstraZeneca has bolstered the standing of Tagrisso as a first-line treatment for locally advanced or metastatic EGFR-mutated ...

The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2. The ...

AstraZeneca's light chain (AL) amyloidosis candidate anselamimab has failed a phase 3 readout, but showed efficacy in a patient subgroup.

If you are middle aged and find you have to hold your phone at arm's length to read, you may have presbyopia - a difficulty focusing on close objects that is usually corrected using glasses ...

Sanofi has been granted a speedy review from the FDA for a gene therapy for geographic atrophy (GA), a complication of age-related macular degeneration (AMD), as it prepares to test it in a ...